Please join us in welcoming the following companies new to HBA corporate partnership in 2023:
GOLD
GoodRx
CEO: Doug Hirsch and Trevor Bezdek
GoodRx partners with pharmaceutical companies through its Pharma Manufacturer Solutions business to better serve the needs of its over 100M unique annual visitors and 865,000 providers that have used GoodRx. GoodRx delivers awareness, access, and adherence solutions to help pharma teams meet their brand and patient support objectives.
TEAL
Cerevel Therapeutics
CEO: Dr. Tony Coles
Cerevel Therapeutics is dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, including Parkinson’s, epilepsy, schizophrenia, and dementiarelated apathy. The company is tackling diseases with a targeted approach to neuroscience that combines expertise in neurocircuitry with a focus on receptor subtype selectivity.
RED
TransPerfect Life Sciences
CEO: Phil Shawe
TransPerfect Life Sciences specializes in supporting the global development and commercialization of drugs, treatments, and devices designed to improve and save lives. Our comprehensive solutions include clinical trial management technology and services (TMF services, eTMF, CTMS, regulated content management, etc.), pharmacovigilance and safety solutions, translation and language services, and call center support. With offices in over 100 cities worldwide, TransPerfect is the ideal partner to ensure that your global launch makes a global impact by driving quality, mitigating compliance risk, and enhancing patient engagement.
MorphoSys
CEO: Jean-Paul Kress, MD
At MorphoSys, we are driven by our mission: More life for people with cancer. As a global commercial-stage biopharmaceutical company, we use groundbreaking science and technologies to discover, develop, and deliver innovative cancer medicines to patients. MorphoSys is headquartered in Planegg, Germany, and has its U.S. operations anchored in Boston, Massachusetts.